Press release
Investigation announced for Investors in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
An investigation for investors in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares over potential securities laws violations.
Investors who purchased shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Protagonist Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Newark, CA based Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. On April 13, 2022, Protagonist disclosed in a filing with the U.S. Securities and Exchange Commission that "[t]he Company has received a letter from United States Food and Drug Administration (the "FDA") indicating the FDA's intent to rescind Breakthrough Therapy Designation for the Company's rusfertide product candidate in polycythemia vera," citing "observed malignancies[.]"
Shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) declined from $38.11 per share on November 15, 2011, to as low as $7.49 per share on May 18, 2022.
Those who purchased shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) here
News-ID: 2629072 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Protagonist
Mumbai Hosts Powerful Premiere of The Protagonist Show and Launch of Sheroes Amo …
In a stirring evening of storytelling, empowerment, and emotion, The Protagonist Show premiered alongside the launch of the book Sheroes Amongst Us - Real Women Real Stories at an exclusive event on June 21. Held in Mumbai, the event was powered by Etherwire.ai, a Multiplaylist Platform, and F13 Happenings.
Co-authored by Falguni Desai and Dr. Amit Nagpal, the book highlights real-life stories of women who transformed adversity into strength, inspiring audiences…
Polycythemia Vera Drugs Market Size in 7MM is expected to grow at a decent CAGR …
DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom, and Japan.
Discover which therapies are expected to grab the Polycythemia Vera Market Share @ Polycythemia Vera Market Outlook- https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Polycythemia Vera Market Report
• In…
Polycythemia Vera Market to Show Remarkable Growth Trends from 2024 to 2034, Del …
DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Polycythemia Vera market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polycythemia Vera Market Forecast
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Polycythemia Vera Market Predicted to See Upsurge Through 2034, Highlights Delve …
DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Polycythemia Vera market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polycythemia Vera Market Forecast
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Polycythemia Vera Market to Observe Impressive Growth During the Forecast Period …
DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Polycythemia Vera market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polycythemia Vera Market Forecast
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Hereditary Hemochromatosis (HH) Market to Witness Growth by 2032, Estimates Delv …
DelveInsight's "Hereditary Hemochromatosis (HH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hereditary Hemochromatosis (HH), historical and forecasted epidemiology as well as the Hereditary Hemochromatosis (HH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Hereditary Hemochromatosis (HH) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
